Dr Reddy's Labs sells 14 ANDAs to Senores Pharma
The acquisition will be funded through the Initial Public Offer proceeds raised by Senores Pharmaceuticals Limited.;
Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (‘ANDAs’) from Dr.Reddy’s Laboratories and its applicable affiliates.
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA.
The addressable opportunity of the acquired ANDAs in the USA is approx. USD 421 Million (MAT December 2024)* as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony.
The acquisition will be funded through the Initial Public Offer (“IPO”) proceeds raised by Senores Pharmaceuticals Limited. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.